- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Dropping Aspirin and continuing with P2Y12 inhibitors safe 1 month after PCI: Study
Boston, MA: Aspirin discontinuation 1-3 months after PCI and continuing with P2Y12 inhibitor monotherapy reduces bleeding risk, according to a recent study in the journal Circulation. The study further found that aspirin discontinuation was not associated with an increased risk of MACE.
P2Y12 receptor blockers are another group of antiplatelet drugs that include: clopidogrel, ticlopidine, ticagrelor, prasugrel, and cangrelor.
Compared to aspirin alone, dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor is known to reduce MACE risk after percutaneous coronary intervention (PCI) or acute coronary syndrome (ACS). However, there is a dispute on whether discontinuing aspirin in favor of P2Y12 inhibitor monotherapy is safe or not.
Michelle L. O'Donoghue, TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Boston, MA, and colleagues conducted a meta-analysis from randomized trials (2001-2020) that studied aspirin discontinuation after 1-3 months of PCI with continued P2Y12 inhibitor monotherapy compared to traditional DAPT. Five trials were included; follow-up duration ranged from 12-15 months post PCI. The primary bleeding and MACE outcomes were the prespecified definitions in each trial.
The study population included 32,145 patients; 14,095 (43.8%) with stable CAD and 18,046 (56.1%) with ACS.
Key findings of the study include:
- In the experimental arm, background use of a P2Y12 inhibitor was clopidogrel in 2649 (16.5%) and prasugrel or ticagrelor in 13,408 (83.5%) of patients.
- In total, 820 patients experienced a primary bleeding outcome and 937 experienced MACE.
- Discontinuation of aspirin therapy 1-3 months post PCI significantly reduced the risk of major bleeding by 40% compared to DAPT (1.97% vs 3.13%), with no observed in the risk of MACE (2.73% vs 3.11%), MI (1.08% vs 1.27%) or death (1.25% vs 1.47%).
- Findings were consistent among patients who underwent PCI for an ACS, in whom discontinuation of aspirin after 1-3 months reduced bleeding by 50% (1.78% vs 3.58%) and did not appear to increase the risk of MACE (2.51% vs 2.98%).
"Discontinuation of aspirin with continued P2Y12 inhibitor monotherapy reduces the risk of bleeding when stopped 1-3 months after PCI. An increased risk of MACE was not observed following discontinuation of aspirin, including patients with ACS," concluded the authors.
The study, "The Safety and Efficacy of Aspirin Discontinuation on a Background of a P2Y12 Inhibitor in Patients after Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis," is published in the journal Circulation.
DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.046251
MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at  editorial@medicaldialogues.in. Contact no. 011-43720751
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751